Lotus Pharmaceutical Co Ltd
TWSE:1795
Net Margin
Lotus Pharmaceutical Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
67.5B TWD |
25%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
770.8B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
391.9B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.4T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
243.8B CHF |
20%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
239.5B USD |
27%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
195.1B CHF |
23%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
158.2B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.7B USD |
13%
|
Lotus Pharmaceutical Co Ltd
Glance View
Lotus Pharmaceutical Co., Ltd., nestled at the intersection of innovation and healthcare, has carved a niche in the competitive pharmaceuticals landscape. Founded in Taiwan, Lotus has evolved into a prominent player, with a strategic focus on the development, manufacturing, and distribution of high-barrier generic drugs and specialty pharmaceuticals. Its journey began as a local pharmaceutical manufacturer but rapidly expanded its horizons through well-timed acquisitions and partnerships. These strategic moves have not only broadened its portfolio but also fortified its foothold in various international markets. The company leverages cutting-edge research and development capabilities to produce cost-effective alternatives to branded medications, which require significant expertise to replicate due to complex manufacturing processes and stringent regulatory requirements. Lotus’s operations hinge on its ability to navigate the intricacies of pharmaceutical regulations and patent landscapes, enabling it to introduce generics as soon as original drug patents expire. This strategic agility allows the company to capture market share quickly and maximize its revenue potential. Lotus Commercializes its products primarily in Asia while also extending its reach to North America and Europe through a network of collaborations and partnerships. Its robust portfolio spans several therapeutic areas, including oncology, central nervous system disorders, and cardiovascular diseases, where the demand for affordable medications is acute. As a result, Lotus not only generates substantial revenue but also plays a pivotal role in enhancing healthcare accessibility and affordability across the globe.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Lotus Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of 24.6%.
You don't have any saved screeners yet